HIV-1-INFECTION

This early-stage study tests two new vaccines designed to prevent HIV. Researchers want to see if they are safe and how the immune system reacts. The trial involves 45 healthy adults without HIV, aged 18 to 55, who will receive injections and be followed for about 16 months.

This early-stage study tests two experimental HIV vaccines (UVAX-1107 and UVAX-1197) in 25 healthy adults without HIV. The main goals are to check if the vaccines are safe and to see how the immune system reacts. Participants will receive injections and have blood and lymph node …

This early-stage study tests whether two experimental HIV vaccine priming regimens are safe and can activate special immune cells that make broad antibodies. 52 healthy adults without HIV will receive the vaccines, with some getting a booster shot later. The goal is to see if the…

This study tests a new long-acting drug called lenacapavir for people with HIV that has become resistant to many current medications. The goal is to see if adding this drug to their existing treatment can lower the amount of virus in their blood. The study involves 72 adults and …

This study tests whether a new once-weekly pill (GS-1720 plus GS-4182) can keep HIV under control as well as the daily pill Biktarvy. About 675 adults with already-suppressed HIV will take either the weekly combo or continue Biktarvy. The goal is to see if the weekly option is sa…

This study tests a new once-daily pill (doravirine/islatravir) for adults with HIV who have never taken HIV medication before. About 537 participants will receive either the new pill or a standard combination pill to see how well they control the virus and if side effects differ.…

This early-stage study tests a single dose of a new long-acting antibody in 20 people with HIV who are not on regular medication. The goal is to check safety and see if the antibody can lower the amount of virus in the blood. Results will help design future studies for both HIV t…

This study tests whether switching to a once-daily pill containing doravirine and islatravir works as well as staying on current HIV medications for people whose virus is already suppressed. About 550 adults with HIV-1 took part. The goal is to see if the new pill keeps the virus…

This study tests whether using simple, fast urine tests and viral load checks at the clinic can help people with HIV stick to their medication and keep the virus under control. About 539 people starting HIV treatment in South Africa will take part. The goal is to see if this appr…

This study tests if switching to a new two-drug combination pill (bictegravir/lenacapavir) works as well as staying on the standard three-drug pill (Biktarvy) for people with HIV-1 who already have the virus under control. About 577 participants will be randomly assigned to one o…

This study tests if people with HIV-1 who are already well-controlled on a daily pill can switch to a once-weekly tablet (islatravir/lenacapavir) without losing viral suppression. About 609 participants will be randomly assigned to either the weekly regimen or continue their curr…

This study tests if people with HIV-1 who are already well-controlled on daily medication can safely switch to a once-weekly pill (islatravir/lenacapavir). About 600 participants will either switch to the weekly pill or stay on their current daily regimen. The main goal is to see…

This study tests whether pomalidomide, a drug used for certain cancers, can help people with HIV control the virus better. It involves 32 adults with well-controlled HIV who will temporarily stop their regular HIV medication to see if pomalidomide keeps the virus at bay. The main…

This study looks at whether switching to a new two-drug combination (bictegravir/lenacapavir) is safe and effective for people with HIV-1 who are already on stable but complex treatment. About 689 participants will be randomly assigned to either the new combo or their current the…

This study tests whether a once-weekly oral combination of two drugs (islatravir and lenacapavir) can keep HIV under control in people whose virus is already suppressed. About 142 adults with HIV who have been on a standard daily pill for at least 24 weeks will take the weekly re…

This study tests a new long-acting HIV treatment that combines two lab-made antibodies (teropavimab and zinlirvimab) with the drug lenacapavir, given as injections every 6 months. It involves 83 adults whose HIV is already well-controlled by daily pills. The goal is to see if swi…

This study is testing a new once-daily pill (Bictegravir/Emtricitabine/Tenofovir Alafenamide) for HIV-1 in adolescents and children. The goal is to see how the drug works in the body, confirm the right dose, and check its safety. About 177 participants aged 2 to 17 who already ha…

This study looks at whether switching older adults (60+) with HIV from a three-drug pill (B/F/TAF) to a two-drug pill (DTG/3TC) is safe and keeps the virus under control. About 240 participants in Kenya will take the new pill for 96 weeks. The main goal is to see how many have de…

This study tests whether adults with HIV who are already well-controlled on a standard three-drug pill can safely switch to a new two-drug pill (DOR/ISL) taken once daily. About 514 participants will be randomly assigned to either continue their current medication or switch to th…

This study tests whether giving two lab-made antibodies can safely keep HIV under control when people stop their regular antiretroviral therapy (ART) for a while. About 32 adults with HIV in Sub-Saharan Africa who are already on ART will receive either the antibodies or a placebo…

This study allows people with HIV-1 who benefited from the two-drug combination doravirine/islatravir in earlier trials to continue receiving it. The main goal is to monitor the long-term safety and side effects of this treatment. It is open to about 2000 participants who are alr…

This study looks at how to best roll out a brief alcohol counseling program (BAI) in HIV clinics across Vietnam. The goal is to reduce unhealthy drinking, which can lead to risky behaviors and HIV spread. Over 3,200 people living with HIV and clinic staff are taking part. One gro…

This study tests a new HIV medicine (B/F/TAF) in full-term newborns who were exposed to HIV but are not infected. The goal is to see if the drug is safe and how the body processes it. Sixteen babies will receive the medicine shortly after birth to help prevent HIV infection.

This study tests whether the nine-valent HPV vaccine can prevent persistent oral HPV infections in 700 men living with HIV. Participants receive either the vaccine or a placebo and are followed for up to four years. The goal is to see if the vaccine reduces the risk of HPV-relate…

This study looks at whether a simple, home-based walking program can help improve blood sugar, cholesterol, and body measurements in people living with HIV who also have metabolic syndrome. Researchers will enroll 50 adults (with and without HIV) and ask them to gradually increas…

This study follows 11 people who previously received an experimental HIV gene therapy called Cal-1. The main goal is to watch for any delayed side effects from the treatment. Researchers will also check how long the modified cells survive in the body. No new treatment is given; t…

This study looks at two markers (CD32a and X) on immune cells of 48 adults with HIV-1 who have undetectable virus levels due to treatment. The goal is to see if these markers relate to the amount of hidden HIV DNA in the body. It does not test a new treatment but aims to improve …

This study looks at 40 people with HIV to see if different types of HIV medications affect the hidden virus (the HIV reservoir) and immune system differently. Researchers want to know if a drug called tenofovir might cause more immune activation and keep the virus hiding longer. …